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Previewsglutamate, may be an important therapeu-
tic approach (Emadi et al., 2014).MYC also
drives this pathway, although in those
studies another enzyme was responsible,
the mitochondrial aldehyde dehydroge-
nase iron-containing enzyme 1 (ADHFE1)
and IDH2 (Terunuma et al., 2014).Whether
both L and D isoforms were present is
not clear, as knockdown of D2HGDH did
not affect levels, yet IDH2 knockdown
prevented their generation. Tumors with
high 2-hydroxyglutarate or DNA methyl-
ation patterns had a worse prognosis and
high glutaminase expression. It was also
shown thatglutaminewas themainprecur-
sor for the 2-hydroxyglutarate. The studies
need to be repeated in hypoxia now.
The levels of L-2-hydroxyglutarate or
the indirect effects on H3K9me3 methyl-
ation could be useful monitors of in vivo
hypoxia metabolism and could help clas-
sify hypoxia areas of tumors in a different
way to using HIF1 or carbonic anhy-
drase 9 staining or pimonidazole binding
(Jubb et al., 2010). Classification of hyp-
oxia in tumors may be helpful for future
personalization of radiotherapy and hyp-
oxia-activated prodrugs. Intlekofer et al.
(2015) indeed showed that upregulation200 Cell Metabolism 22, August 4, 2015 ª201of H3K9me3 correlated with HIF1 in glio-
blastoma, but the time course of reversal
of L-2-hydroxyglutarate after reoxyge-
nation or demethylation of H3K9me3 is
unclear and needs further investigation.
For example, if there is discordance of
overlap between HIF1a and these path-
ways in other tumor types, deciphering
which of the biological pathways is active
in a tumor is important. Individual tumors
show great heterogeneity in the extent
of hypoxic areas and genes expressed
in them, and some with low HIF1a
expression could potentially be driven by
this metabolic pathway and would pro-
duce different types of hypoxia biology,
relevant to interaction with drugs and
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High adipose expression of NNMT, an enzyme that converts nicotinamide to 1-methyl-nicotinamide, corre-
lates with adiposity. Though murine NNMT knockdown in fat and liver prevents weight gain on high-fat
diet, Hong et al. (2015) now show that high hepatic expression of NNMT improves lipid parameters via
SIRT1 stabilization.NAD+ is the central coenzyme for the
oxidation of fuel and for interconversion
of different classes of metabolites,
including the conversion of carbohy-
drates to lipids (Belenky et al., 2007).
NAD+ is typically reduced to NADH in
fuel oxidation steps, whereas NADPH isreoxidized to NADP+ in lipogenic reac-
tions. Cells control major processes
such as glycolysis, gluconeogenesis,
and lipogenesis, in part, with changes in
gene expression programs. Several such
programs are modulated by sirtuin 1
(SIRT1), an NAD+-dependent proteinlysine deacetylase (Chang and Guarente,
2014). SIRT1 is not a redox enzyme
but rather an NAD+-consuming enzyme,
whose activities as a regulator of gene
expression and protein function link lysine
deacetylation to the turnover of NAD+.
The products of SIRT1 are a deacetylated
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Previewsprotein plus two metabolites: nicotin-
amide (Nam) and acetylated ADPribose.
Nam, one of three NAD+ precursor vita-
mins (Bogan and Brenner, 2008), can be
salvaged, i.e., used in resynthesis of
NAD+. However, Nam cannot be salvaged
if it is N-methylated by the product of the
Nam N-methyltransferase gene (NNMT),
thereby forming 1-methyl-nicotinamide
(meNam).
Because NAD+ is required for fuel
oxidation and is consumed by sirtuins,
the competition between NNMT and
NAD+ salvage suggests that NNMT could
be a ‘‘bad actor’’ that might limit fuel
oxidation and promote the storage of fat.
If NNMT is highly expressed, then Nam
might not be salvageable such that
NAD+-dependent processes would be
limited. This is exactly what was reported
for adipose expression of NNMT (Kraus
et al., 2014). In that study, an antisense
oligonucleotide that reduced expression
of NNMT in liver and white adipose tissue
(WAT) allowed mice to resist weight gain
on high-fat diet (HFD). Knocking down
NNMT in fat cells increased a polyamine
catabolic cycle (PCC) gene expression
program and oxygen consumption. Inter-
estingly, the meNam product of NNMT
had much the same effect as NNMT
knockdown in cultured adipocytes, which
was attributed to inhibition of NNMT
(Kraus et al., 2014).
In a recent paper published in Nature
Medicine, Hong et al. showed that hepatic
NNMT and meNam are ‘‘good actors’’
with respect to protection from some
effects of HFD-induced obesity (Hong
et al., 2015). Though adipose NNMT
expression correlates with adiposity in
people and mice (Kraus et al., 2014),
Hong et al. found that hepatic NNMT
expression correlates with lower serum
lipids in mice and morbidly obese people
(Hong et al., 2015). Beneficial effects of
hepatic NNMT were attributed to the
meNam product, which stabilized SIRT1
protein and thereby limited lipogenic
gene expression (Hong et al., 2015). The
authors found that NNMT knockdown
in hepatocytes lowered gluconeogenic
gene expression and elevated lipogenic
gene expression (Hong et al., 2015).
Moreover, NNMT overexpression in-
creased expression of gluconeogenic
bypass genes in a manner that was remi-
niscent of the SIRT1 program (Rodgers
et al., 2005). Earlier, pharmacological ef-fects of meNam in adipose tissue were
attributed to NNMT inhibition—this was
rationalized as a desirable effect because
NNMT activity could deplete S-adenosyl
methionine and NAD+ cofactors, thereby
dampening PCC gene expression (Kraus
et al., 2014). Whereas NNMT overexpres-
sion depressed NAD+ levels in WAT
(Kraus et al., 2014), such changes were
not seen in liver (Kraus et al., 2014, Hong
et al., 2015). However, NAD+ is one of
four related NAD coenzymes, and neither
study used approaches that quantify
changes in the NAD metabolome (Tram-
mell and Brenner, 2013).
If NNMT overexpression and the
meNam product do not greatly change
hepatocyte NAD+ but increase SIRT1
signaling, what might meNam do? The
breakthrough result was one in which
SIRT1 protein stability was increased
and polyubiquitylation decreased by
meNam (Hong et al., 2015). How meNam
blocks SIRT1 polyubiquitylation was not
investigated, though it is possible that
meNam or a meNam metabolite blocks
a ubiquitin ligase. By stabilizing SIRT1,
meNam promoted the SIRT1 gene ex-
pression program in hepatocytes. In
addition, pharmacological meNam sup-
plementation to HFD lowered serum and
hepatic lipids, though it did not block
weight gain (Hong et al., 2015).
How can NNMT knockdown promote
resistance to HFD if NNMT expression
and the meNam product also cause
some metabolic resistance to the effects
of HFD? First, though the antisense re-
agent dampened expression in WAT and
liver, the cell-autonomous effects of
NNMT appeared to be stronger in WAT
than in liver (Kraus et al., 2014), such
that resistance to weight gain was likely
mediated by increased oxygen consump-
tion in WAT. Second, because oral
meNam may largely be absorbed by the
liver in first pass metabolism, it may stabi-
lize hepatic SIRT1 and not be readily
available to counteract caspase-depen-
dent degradation of SIRT1 in WAT (Chal-
kiadaki and Guarente, 2012). Tissue-
specific knockdown and overexpression
experiments and/or alternative formula-
tions of meNam will be needed to clarify
the seemingly disparate results.
It may be helpful to appreciate that
NNMT and SIRT1 are neither ‘‘bad’’ nor
‘‘good’’ in all tissues at all times. Animals
have deep evolutionary programming toCell Metabolism 2gain weight and store fuel when excess
calories are available (Ghanta et al.,
2013). The hepatic SIRT1 program, which
promotes gluconeogenic gene expres-
sion, may be diabetogenic under some
conditions and homeostatic under other
conditions. Moreover, in WAT, the ability
of NNMT to depress NAD+ salvage may
be highly advantageous in order for an
animal to maximize seasonal weight gain
and protect against famine. We suggest
that the tendency of WAT to increase
expression of NNMT may aid in fat stor-
age, whereas the activity of NNMT as a
SIRT1 stabilizer may allow the liver to
cope with the accumulation of body fat
produced by episodes of overnutrition.
Experiments involving a genetic or
pharmacological intervention added to
HFD are unlike the human experiencewith
evidence-based weight loss. Because
best available care for overweight condi-
tions consists of reducing energy intake
and/or increasing energy expenditure, in-
terventions might be tested in animals
coming off, rather than remaining on,
HFD. In the context of experimental sub-
jects coming off HFD who are monitored
for metabolic health and weight loss, it
will be interesting to see whether there
are beneficial effects of NNMT knock-
down inWAT or increasingmeNam in liver
and to determine if such interventions can
be combined.
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